P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018) - Cheng, A; Abou-Alfa, G; Ren, Z; Assenat, E; Cubillo, A; Pluntke, S; Rimassa, L; Ross, P; Wyrwicz, L; Hou, J; Li, C; Wu, J; et al.